Navigation Links
Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
Date:12/3/2013

e">Michael A. Martino, President and CEO of Ambit. "We believe that our data demonstrates the clinical value and benefit of quizartinib for patients in an area of clear and high unmet medical need.  We look forward to presenting our data at ASH next week and anticipate a high level of clinical enthusiasm."

Data from quizartinib studies will be presented at the ASH 55th Annual Meeting at the Ernest Morial Convention Center in New Orleans, LA on December 9, 2013. 

Oral Presentations:

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib. The data will be presented by Dr. Jorge Cortes at 3:00 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Quizartinib Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Experience From The AML Pilot Trial: This is the first presentation of quizartinib use in combination with chemotherapy in newly diagnosed older AML patients, testing the feasibility and dose which could be given sequentially following conventional chemotherapy in patients over the age of 60 years. The data will be presented by Dr. Alan Burnett at 5:15 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Results of Phase 1 Study of Quizartinib In Combination with Induction and Consolidation Chemotherapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: This dose escalation study is the first to report data on quizartinib in combination with standard indu
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
2. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
3. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
4. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
5. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
6. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
7. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015  Oxis International, Inc. (OXIS) (OXI.PA) ... and commercialization, announced today Oxis CEO Tony Cataldo ... Oxis common shares on the Euronext exchange. Oxis shares ... symbol OXIS.   Oxis Chairman and CEO ... move forward with its strategies launched in 2014 and ...
(Date:3/31/2015)... , March 31, 2015 Biorasi ... announced a strategic partnership with Medidata , ... clinical research in life sciences. Offering therapeutic expertise ... has deployed Medidata,s electronic data capture (EDC), management ... Phase I through IV global clinical trial business. ...
(Date:3/31/2015)... SAN DIEGO , March 31, 2015 /PRNewswire/ ... of biopharmaceutical contract development and manufacturing services, ... more top pharmaceutical companies to its growing ... cGMP-produced crystal-based drug products using Althea,s ... additional companies, a total of 4 out ...
Breaking Medicine Technology:Oxis International Inc. Announces Request for Euronext Trading Suspension 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4Althea's New Drug Formulation Technology Gains Attention from Two More Top Pharmaceutical Companies 2
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration has ... of using beard hair to fill in balding areas ... has now become an absolute option for giving patients the best ... believe that beard to scalp hair transplant can be a patients ... as dense as we would like it,” says Dr. Parsa Mohebi. ...
(Date:3/31/2015)... 2015 The American College of Traditional ... for April will include interesting workshops, lectures and more. ... 9-11 a.m. April 6, ACTCM welcomes the newest cohort. ... the Pioneer Square Campus located at 555 DeHaro St. ... April 14, Students will be updated on the upcoming ...
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address ... University’s Commencement ceremony on May 9, 2015 and ... recognition of her eminent career as a nurse, public ... caregiver and senior staff nurse at Brigham and Women’s ... leadership roles, including President of the American Nurses Association ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Simeon Boyd, ... a nearly $4 million, five-year grant from the National ... team of physicians and scientists from more than 10 ... including Australia, Brazil, Bulgaria, Germany, Hungary, Italy and the ... the bony plates of the skull in infants. , ...
(Date:3/31/2015)... Medical DNA Labs, LLC, An Affiliate ... for Laboratory Accreditation by COLA, a national healthcare accreditation ... apply rigid standards of quality in day-to-day operations, demonstrate ... pass a rigorous on-site laboratory survey. Medical DNA ... of a long-term commitment to provide quality service to ...
Breaking Medicine News(10 mins):Health News:Is Beard to Scalp Hair Transplant the Future? 2Health News:ACTCM Announces April Event Schedule 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 2Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 3Health News:Local Medical DNA Labs, LLC. Recognized for Quality Laboratory Services 2
... it is not. Yet its,success is none-the-less impressive. ... both worldwide and in the,U.S. since the turn ... for virtual,reality in surgery, medical education, therapy and ... Virtual Reality Market in the US Healthcare,Sector: Markets ...
... Oct. 19 How far can a bright, ... for one super smile could take YOU,all the ... at the People,s,Choice Awards. Listen to this ... journalists can access video, audio, text, graphics and,photos ...
... to fumes at home less likely to pass exams, research ... is secondhand smoke a threat to teen health, it can ... , Researchers at Temple University found that 16- and 18-year-olds ... likely to pass standardized tests than their peers. , They ...
... With safety issues making,headlines, pharmaceutical and ... Organizations are relying on their quality function,to ... Proper,staffing of quality roles is just one ... study by pharmaceutical benchmarking leader Best,Practices, LLC ...
... Single-Payer ... Healthcare, ... thanks Al Gore for,his forceful new words in support of the ... and that is,succeeding in nearly every other industrialized democracy. The ...
... MENTOR, Ohio, Oct. 19 STERIS Corporation,(NYSE: ... its fiscal 2008 second,quarter earnings release before the ... conference call at 10:00 a.m. Eastern time. The ... at http://www.steris-ir.com or via phone,by dialing ...
Cached Medicine News:Health News:Virtual Reality Technology Finds Ready and Willing Market in Healthcare 2Health News:Secondhand Smoke Hurts Kids' Grades 2Health News:Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance 2Health News:National Nurses Movement Lauds Al Gore for Leadership on Single-Payer Healthcare 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call 3
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... on-board capacity of 57 assays ... 146 tests, the CX1000 PRO ... so you can maximize your ... workload. The CX1000 PRO creates ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance....
Medicine Products: